High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma (vol 100, pg 1444, 2009)

被引：0

作者：

Marechal, R.

Demetter, P.

Nagy, N.

Berton, A.

Decaestecker, C.

Polus, M.

Closset, J.

Deviere, J.

Salmon, I.

Van Laethem, J-L

机构：

来源：

BRITISH JOURNAL OF CANCER | 2010年 / 103卷 / 06期

关键词：

D O I：

10.1038/sj.bjc.6605894

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Correction to: British Journal of Cancer (2009) 100, 1444–1451. doi:10.1038/sj.bjc.6605020 Upon publication of this paper in 2009, the authors noticed two errors – one in the abstract and one within the Results section. On page 1444 (Abstract), the seventh sentence should read as follows: ‘In a combining analysis, patients with a CXCR7high/CXCR4high tumour had a significantly shorter DFS and OS than patients with a CXCR4low/CXCR7low tumour’.

引用

页码：930 / 930

页数：1

共 50 条

[41] Non-Ampullary Duodenal Adenocarcinoma: Factors Important for Relapse and Survival (vol 100, pg 144, 2009)
Struck, Aaron
Howard, Thomas
Chiorean, Elena G.
Clarke, Jeffrey M.
Riffenburgh, Robert
Cardenes, Higinia R.
JOURNAL OF SURGICAL ONCOLOGY, 2009, 100 (05) : 434 - 434
[42] High Nuclear Expression of CXCR4 Is Associated with Metastases and Decreased Survival in Hormone Sensitive Breast Cancer
Cronin, P. A.
O'Connell, F.
Wang, J. H.
Redmond, H. P.
CANCER RESEARCH, 2009, 69 (24) : 658S - 658S
[43] CXCR4, CXCR7 and CXCL12 expression is not a predictive factor in patients with resected pancreatic cancer - results from the CONKO-001 trial
Striefler, J. K.
Wislocka, L.
Sinn, M.
Denkert, C.
Juehling, A.
Pelzer, U.
Bischoff, S.
Bahra, M.
Oettle, H.
Blaeker, H.
Riess, H.
Lohneis, P.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 258 - 259
[44] CXCR4 expression in tumor associated circulating cells of patients with pancreatic cancer is prognostic for progression and overall survival.
Gardner, Kirby P.
Tsai, Susan
Aldakkak, Mohammed
Gironda, Stephen
Tang, Cha-Mei
Adams, Daniel L.
CANCER RESEARCH, 2021, 81 (13)
[45] Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets
Kocher, Florian
Puccini, Alberto
Untergasser, Gerold
Martowicz, Agnieszka
Zimmer, Kai
Pircher, Andreas
Baca, Yasmine
Xiu, Joanne
Haybaeck, Johannes
Tymoszuk, Piotr
Goldberg, Richard M.
Petrillo, Angelica
Shields, Anthony F.
Salem, Mohamed E.
Marshall, John L.
Hall, Michael
Korn, W. Michael
Nabhan, Chadi
Battaglin, Francesca
Lenz, Heinz-Josef
Lou, Emil
Choo, Su-Pin
Toh, Chee-Keong
Gasteiger, Silvia
Pichler, Renate
Wolf, Dominik
Seeber, Andreas
CLINICAL CANCER RESEARCH, 2022, 28 (22) : 4957 - 4967
[46] High TGFβ1 expression may ameliorate the poor survival associated with high KRAS expression in patients with resectable pancreatic carcinoma
Glazer, Evan Scott
Welsh, Eric
Teer, Jamie
Malafa, Mokenge P.
CANCER RESEARCH, 2016, 76
[47] Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival - Comments
Oyesiku, Nelson M.
Kuo, John S.
Cronk, Katharine M.
Bruce, Jeffrey N.
Glick, Roberta
NEUROSURGERY, 2007, 61 (03) : 578 - 579
[48] CXCR4, CXCR7 and CXCL12 expression is not a prognostic predictive factor in patients with resected pancreatic cancer - results from the CONKO-001 trial
Striefler, J.
Wislocka, L.
Sinn, M.
Pelzer, U.
Denkert, C.
Juehling, A.
Bischoff, S.
Bahra, M.
Hendrik, B.
Oettle, H.
Riess, H.
Lohneis, P.
ANNALS OF ONCOLOGY, 2016, 27 : 104 - 104
[49] High expression of syndecan-4 is related to clinicopathological features and poor prognosis of pancreatic adenocarcinoma
Zhu, Yufei
Zheng, Dijie
Lei, Linhan
Cai, Kun
Xie, Huahua
Zheng, Jian
Yu, Chao
BMC CANCER, 2022, 22 (01)
[50] High expression of syndecan-4 is related to clinicopathological features and poor prognosis of pancreatic adenocarcinoma
Yufei Zhu
Dijie Zheng
Linhan Lei
Kun Cai
Huahua Xie
Jian Zheng
Chao Yu
BMC Cancer, 22

← 1 2 3 4 5 →